Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | EML4 - ALK |
| Therapy | Crizotinib |
| Indication/Tumor Type | spindle cell sarcoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| EML4 - ALK | spindle cell sarcoma | predicted - sensitive | Crizotinib | Case Reports/Case Series | Actionable | In a clinical case study, treatment with Xalkori (crizotinib) resulted in a partial response in a patient with myxoid spindle cell tumor harboring EML4-ALK (PMID: 42150148). | 42150148 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (42150148) | Use of ALK Inhibitors in Patients With Nonlung Malignancies Bearing ALK Alteration Prolongs Treatment Duration. | Full reference... |